Literature DB >> 27329248

Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumab.

A Heine1, G Kristiansen2, H H Schild3, P Brossart4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27329248     DOI： 10.1093/annonc/mdw243

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  11 in total

1.  Efficacy of PD-1 inhibitors combined with pegylated liposomal doxorubicin and dacarbazine compared with liposomal doxorubicin and dacarbazine in advanced leiomyosarcoma patients: a retrospective, single-institutional cohort study.

Authors:  Zhichao Tan; Xinyu Wang; Jiayong Liu; Zhengfu Fan; Tian Gao; Chujie Bai; Ruifeng Xue; Shu Li; Lu Zhang
Journal:  Ann Transl Med       Date:  2022-09

2.  Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study.

Authors:  Hanhui Zou; Liming Xia; Gu Jin; Hao Wu; Wenkang Qian; Dongdong Jia; Haichao Xu; Tao Li
Journal:  Cancer Manag Res       Date:  2022-05-11       Impact factor: 3.602

3.  Indian experience with immunotherapy in sarcoma and gastrointestinal stromal tumors: a retrospective study.

Authors:  Rohit Reddy; Raja Mounika Velagapudi; Sindhura Durga Chitikela; Adarsh Barwad; Shakti Shrivastava; Ekta Dhamija; Shamim Ahmed Shamim; Sarthak Tripathy; Rambha Pandey; Sameer Rastogi
Journal:  Future Sci OA       Date:  2022-04-20

4.  Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.

Authors:  Takeshi Iwasaki; Kenichi Kohashi; Yu Toda; Shin Ishihara; Yuichi Yamada; Yoshinao Oda
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-20       Impact factor: 4.553

5.  Tumor regression after combination of radiation and PD-1 antibody nivolumab treatment in a patient with metastatic mediastinal leiomyosarcoma: a case report.

Authors:  Chen Xi; Zhang Wencheng; Qian Dong; Guan Yong; Yan Cihui; Wang Yuwen; Zhang Hualei; Er Puchun; Pang Qingsong; Wang Ping
Journal:  Cancer Biol Ther       Date:  2018-11-02       Impact factor: 4.742

6.  Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.

Authors:  Marie Kostine; Inge H Briaire-de Bruijn; Arjen H G Cleven; Carly Vervat; Willem E Corver; Marco W Schilham; Els Van Beelen; Hester van Boven; Rick L Haas; Antoine Italiano; Anne-Marie Cleton-Jansen; Judith V M G Bovée
Journal:  Oncoimmunology       Date:  2017-10-26       Impact factor: 8.110

Review 7.  Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.

Authors:  Anna Maria Frezza; Silvia Stacchiotti; Alessandro Gronchi
Journal:  BMC Med       Date:  2017-06-02       Impact factor: 8.775

Review 8.  A review of soft-tissue sarcomas: translation of biological advances into treatment measures.

Authors:  Ngoc T Hoang; Luis A Acevedo; Michael J Mann; Bhairavi Tolani
Journal:  Cancer Manag Res       Date:  2018-05-10       Impact factor: 3.989

9.  Case Report: Complete Response to Antiangiogenesis and Immune Checkpoint Blockade in an Unresectable MMR-Deficient Leiomyosarcoma Harboring Biallelic Loss of PTEN.

Authors:  Xi Guo; Suyao Li; Hanxing Tong; Yong Zhang; Yuan Ji; Rongyuan Zhuang; Chenlu Zhang; Yang You; Weiqi Lu; Yuhong Zhou
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

10.  Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol.

Authors:  Jennifer le Guevelou; Colin Debaigt; Esma Saada-Bouzid; Julien Viotti; Nazim Khalladi; David Thibouw; Nicolas Penel; Marie Pierre Sunyach; Laurence Moureau-Zabotto; Mohamed Benchalal; Ovidiu Veresezan; Anne Ducassou; Cecile le Pechoux; Maria Jolnerovski; Celine Bazille; Dominique Vaur; Alexandre Escande; Raphael Serre; Christine Lovera; Juliette Thariat
Journal:  BMJ Open       Date:  2020-09-23       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.